binding affinity News and Research

RSS

Optimal monoclonal antibodies against SARS-CoV-2 variants

Researchers screen different monoclonal antibodies to identify an optimal mAb with higher binding affinity to the receptor-binding domain of SARS-CoV-2.

10 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Emerging SARS-CoV-2 B.1.619 and B.1.620 variants in South Korea

Researchers investigate the spread and transmission ability of SARS-CoV-2 lineages B.1.619 and B.1.620 in South Korea.

9 Jan 2022

SARS-CoV-2 Omicron a product of offensive evolution with compromised antigenicity

Researchers investigate the relationship between the SARS-CoV-2 Omicron variant and immune system based on self/nonself short constituent sequences.

9 Jan 2022

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Researchers from India have now successfully grown and isolated the Omicron variant from hamsters in vivo with further culturing in the Vero CCL-81 cells in vitro, in a step forward towards testing the effectiveness of existing SARS-CoV-2 vaccines and generation of new Omicron appropriate vaccines.

7 Jan 2022

Serological antibody response to SARS-CoV-2 infection at a population level

The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.

6 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.

28 Dec 2021

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

28 Dec 2021

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Researchers compare the obtained binding affinities to wild-type and Delta spike proteins to determine the impact of Omicron mutations.

23 Dec 2021

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

New study results highlight that Omicron has an increased affinity to ACE-2 receptors, therefore, has increased infectivity, viral load, and transmissibility compared to other variants of concern, including the Delta variant.

22 Dec 2021

binding affinity News and Research

Optimal monoclonal antibodies against SARS-CoV-2 variants

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Emerging SARS-CoV-2 B.1.619 and B.1.620 variants in South Korea

SARS-CoV-2 Omicron a product of offensive evolution with compromised antigenicity

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Serological antibody response to SARS-CoV-2 infection at a population level

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

The impact of natural selection on sequence diversity in SARS-CoV-2

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News